Judge might reopen GSK paroxetine caseBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i800 (Published 08 February 2016) Cite this as: BMJ 2016;352:i800
- Clare Dyer
- 1The BMJ
A High Court compensation claim against the pharmaceutical company GlaxoSmithKline (GSK) over its antidepressant paroxetine may be revived, five years after the withdrawal of legal aid funding put it on hold shortly before the trial was due to start on 1 February 2011.
At the High Court in London, Mr Justice Foskett refused GSK an order to bring the case to a permanent halt.
The 103 claimants, whose new solicitors, Fortitude Law, had arranged commercial litigation funding, said …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial